Literature DB >> 31945408

Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2).

Pui Y Lee1, Erinn S Kellner2, Yuelong Huang3, Elissa Furutani4, Zhengping Huang5, Wayne Bainter6, Mohammed F Alosaimi7, Kelsey Stafstrom6, Craig D Platt6, Tali Stauber8, Somech Raz8, Irit Tirosh9, Aaron Weiss10, Michael B Jordan11, Christa Krupski12, Despina Eleftheriou13, Paul Brogan13, Ali Sobh14, Zeina Baz15, Gerard Lefranc16, Carla Irani17, Sara S Kilic18, Rasha El-Owaidy19, M R Lokeshwar20, Pallavi Pimpale21, Raju Khubchandani21, Eugene P Chambers22, Janet Chou6, Raif S Geha6, Peter A Nigrovic23, Qing Zhou24.   

Abstract

BACKGROUND: Deficiency of adenosine deaminase 2 (DADA2) is a syndrome with pleiotropic manifestations including vasculitis and hematologic compromise. A systematic definition of the relationship between adenosine deaminase 2 (ADA2) mutations and clinical phenotype remains unavailable.
OBJECTIVE: We sought to test whether the impact of ADA2 mutations on enzyme function correlates with clinical presentation.
METHODS: Patients with DADA2 with severe hematologic manifestations were compared with vasculitis-predominant patients. Enzymatic activity was assessed using expression constructs reflecting all 53 missense, nonsense, insertion, and deletion genotypes from 152 patients across the DADA2 spectrum.
RESULTS: We identified patients with DADA2 presenting with pure red cell aplasia (n = 5) or bone marrow failure (BMF, n = 10) syndrome. Most patients did not exhibit features of vasculitis. Recurrent infection, hepatosplenomegaly, and gingivitis were common in patients with BMF, of whom half died from infection. Unlike patients with DADA2 with vasculitis, patients with pure red cell aplasia and BMF proved largely refractory to TNF inhibitors. ADA2 variants associated with vasculitis predominantly reflected missense mutations with at least 3% residual enzymatic activity. In contrast, pure red cell aplasia and BMF were associated with missense mutations with minimal residual enzyme activity, nonsense variants, and insertions/deletions resulting in complete loss of function.
CONCLUSIONS: Functional interrogation of ADA2 mutations reveals an association of subtotal function loss with vasculitis, typically responsive to TNF blockade, whereas more extensive loss is observed in hematologic disease, which may be refractory to treatment. These findings establish a genotype-phenotype spectrum in DADA2.
Copyright © 2020 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adenosine deaminase 2; DADA2; bone marrow failure; pure red cell aplasia; vasculitis

Mesh:

Substances:

Year:  2020        PMID: 31945408      PMCID: PMC7282972          DOI: 10.1016/j.jaci.2019.12.908

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  30 in total

1.  SIFT: Predicting amino acid changes that affect protein function.

Authors:  Pauline C Ng; Steven Henikoff
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

2.  Novel ADA2 mutation presenting with neutropenia, lymphopenia and bone marrow failure in patients with deficiency in adenosine deaminase 2 (DADA2).

Authors:  Rohit R Ghurye; Kruthika Sundaram; Frances Smith; Barnaby Clark; Michael A Simpson; Lynette Fairbanks; Zoe Adhya; Ghulam J Mufti; Judith C W Marsh; Mohammad A A Ibrahim
Journal:  Br J Haematol       Date:  2019-03-28       Impact factor: 6.998

3.  A Monogenic Disease with a Variety of Phenotypes: Deficiency of Adenosine Deaminase 2.

Authors:  Seza Özen; Ezgi Deniz Batu; Ekim Z Taşkıran; Hatice Asuman Özkara; Şule Ünal; Naz Güleray; Abdulsamet Erden; Ömer Karadağ; Fatma Gümrük; Mualla Çetin; Hafize Emine Sönmez; Yelda Bilginer; Deniz Çağdaş Ayvaz; Ilhan Tezcan
Journal:  J Rheumatol       Date:  2019-05-01       Impact factor: 4.666

4.  Screening of 181 Patients With Antibody Deficiency for Deficiency of Adenosine Deaminase 2 Sheds New Light on the Disease in Adulthood.

Authors:  Johanna Schepp; Michele Proietti; Natalie Frede; Mary Buchta; Katrin Hübscher; Jessica Rojas Restrepo; Sigune Goldacker; Klaus Warnatz; Jana Pachlopnik Schmid; Andrea Duppenthaler; Vassilios Lougaris; Ignacio Uriarte; Susan Kelly; Michael Hershfield; Bodo Grimbacher
Journal:  Arthritis Rheumatol       Date:  2017-07-05       Impact factor: 10.995

5.  Treatment Strategies for Deficiency of Adenosine Deaminase 2.

Authors:  Amanda K Ombrello; Jing Qin; Patrycja M Hoffmann; Parag Kumar; Deborah Stone; Anne Jones; Tina Romeo; Beverly Barham; Gineth Pinto-Patarroyo; Camilo Toro; Ariane Soldatos; Qing Zhou; Natalie Deuitch; Ivona Aksentijevich; Sherry L Sheldon; Susan Kelly; Ada Man; Karyl Barron; Michael Hershfield; Willy A Flegel; Daniel L Kastner
Journal:  N Engl J Med       Date:  2019-04-18       Impact factor: 91.245

6.  Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy.

Authors:  Paulina Navon Elkan; Sarah B Pierce; Reeval Segel; Tom Walsh; Judith Barash; Shai Padeh; Abraham Zlotogorski; Yackov Berkun; Joseph J Press; Masha Mukamel; Isabel Voth; Philip J Hashkes; Liora Harel; Vered Hoffer; Eduard Ling; Fatos Yalcinkaya; Ozgur Kasapcopur; Ming K Lee; Rachel E Klevit; Paul Renbaum; Ariella Weinberg-Shukron; Elif F Sener; Barbara Schormair; Sharon Zeligson; Dina Marek-Yagel; Tim M Strom; Mordechai Shohat; Amihood Singer; Alan Rubinow; Elon Pras; Juliane Winkelmann; Mustafa Tekin; Yair Anikster; Mary-Claire King; Ephrat Levy-Lahad
Journal:  N Engl J Med       Date:  2014-02-19       Impact factor: 91.245

7.  Adenosine deaminase type 2 deficiency masquerading as GATA2 deficiency: Successful hematopoietic stem cell transplantation.

Authors:  Amy P Hsu; Robert R West; Katherine R Calvo; Jennifer Cuellar-Rodriguez; Mark Parta; Susan J Kelly; Nancy J Ganson; Michael S Hershfield; Steven M Holland; Dennis D Hickstein
Journal:  J Allergy Clin Immunol       Date:  2016-04-06       Impact factor: 10.793

8.  Disrupted N-linked glycosylation as a disease mechanism in deficiency of ADA2.

Authors:  Pui Y Lee; Yuelong Huang; Qing Zhou; Oskar Schnappauf; Michael S Hershfield; Ying Li; Nancy J Ganson; Natalia Sampaio Moura; Ottavia M Delmonte; Scellig S Stone; Michael J Rivkin; Sung-Yun Pai; Todd Lyons; Robert P Sundel; Victor W Hsu; Luigi D Notarangelo; Ivona Aksentijevich; Peter A Nigrovic
Journal:  J Allergy Clin Immunol       Date:  2018-06-21       Impact factor: 10.793

9.  Warts and DADA2: a Mere Coincidence?

Authors:  Katrijn Arts; Jenna R E Bergerson; Amanda K Ombrello; Morgan Similuk; Andrew J Oler; Anahita Agharahimi; Emily M Mace; Mike Hershfield; Carine Wouters; Lien De Somer; Marie-Anne Morren; Rebeca Perez-de Diego; Leen Moens; Alexandra F Freeman; Isabelle Meyts
Journal:  J Clin Immunol       Date:  2018-11-01       Impact factor: 8.542

Review 10.  Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment.

Authors:  Isabelle Meyts; Ivona Aksentijevich
Journal:  J Clin Immunol       Date:  2018-06-27       Impact factor: 8.317

View more
  31 in total

Review 1.  Molecular mechanisms of phenotypic variability in monogenic autoinflammatory diseases.

Authors:  Ivona Aksentijevich; Oskar Schnappauf
Journal:  Nat Rev Rheumatol       Date:  2021-05-25       Impact factor: 20.543

2.  Deficiency of Adenosine Deaminase 2 (DADA2): Hidden Variants, Reduced Penetrance, and Unusual Inheritance.

Authors:  Oskar Schnappauf; Qing Zhou; Natalia Sampaio Moura; Amanda K Ombrello; Drew G Michael; Natalie Deuitch; Karyl Barron; Deborah L Stone; Patrycja Hoffmann; Michael Hershfield; Carolyn Applegate; Hans T Bjornsson; David B Beck; P Dane Witmer; Nara Sobreira; Elizabeth Wohler; John A Chiorini; The American Genome Center; Clifton L Dalgard; Nih Intramural Sequencing Center; Daniel L Kastner; Ivona Aksentijevich
Journal:  J Clin Immunol       Date:  2020-07-08       Impact factor: 8.317

Review 3.  Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach.

Authors:  Peter A Nigrovic; Pui Y Lee; Hal M Hoffman
Journal:  J Allergy Clin Immunol       Date:  2020-11       Impact factor: 10.793

Review 4.  Polyarteritis nodosa and deficiency of adenosine deaminase 2 - Shared genealogy, generations apart.

Authors:  Zhengping Huang; Tianwang Li; Peter A Nigrovic; Pui Y Lee
Journal:  Clin Immunol       Date:  2020-04-07       Impact factor: 3.969

Review 5.  Treatment of immune-mediated cytopenias in patients with primary immunodeficiencies and immune regulatory disorders (PIRDs).

Authors:  Markus G Seidel
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 6.  Mechanisms of vascular inflammation in deficiency of adenosine deaminase 2 (DADA2).

Authors:  Pui Y Lee; Ivona Aksentijevich; Qing Zhou
Journal:  Semin Immunopathol       Date:  2022-02-17       Impact factor: 9.623

7.  Widening the Neuroimaging Features of Adenosine Deaminase 2 Deficiency.

Authors:  A F Geraldo; R Caorsi; D Tortora; C Gandolfo; R Ammendola; M Alessio; G Conti; A Insalaco; S Pastore; S Martino; I Ceccherini; S Signa; M Gattorno; A Rossi; M Severino
Journal:  AJNR Am J Neuroradiol       Date:  2021-02-25       Impact factor: 3.825

Review 8.  Expanding spectrum of DADA2: a review of phenotypes, genetics, pathogenesis and treatment.

Authors:  Benzeeta Pinto; Prateek Deo; Susmita Sharma; Arshi Syal; Aman Sharma
Journal:  Clin Rheumatol       Date:  2021-03-31       Impact factor: 2.980

9.  Comprehensive analysis of ADA2 genetic variants and estimation of carrier frequency driven by a function-based approach.

Authors:  Hyuk Jee; Zhengping Huang; Samantha Baxter; Yuelong Huang; Maria L Taylor; Lauren A Henderson; Sofia Rosenzweig; Aman Sharma; Eugene P Chambers; Michael S Hershfield; Qing Zhou; Fatma Dedeoglu; Ivona Aksentijevich; Peter A Nigrovic; Anne O'Donnell-Luria; Pui Y Lee
Journal:  J Allergy Clin Immunol       Date:  2021-05-15       Impact factor: 10.793

10.  Plasma Adenosine Deaminase (ADA)-1 and -2 Demonstrate Robust Ontogeny Across the First Four Months of Human Life.

Authors:  Oludare A Odumade; Alec L Plotkin; Jensen Pak; Olubukola T Idoko; Matthew A Pettengill; Tobias R Kollmann; Al Ozonoff; Beate Kampmann; Ofer Levy; Kinga K Smolen
Journal:  Front Immunol       Date:  2021-05-27       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.